Vaishampayan UN - Search Results

1

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. McKay RR, et al. Among authors: vaishampayan un. Eur Urol. 2014 Mar;65(3):577-84. doi: 10.1016/j.eururo.2013.08.012. Epub 2013 Aug 15. Eur Urol. 2014. PMID: 23962746 Free PMC article.

2

Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.

Vaishampayan U, Flaherty L, Du W, Hussain M. Vaishampayan U, et al. Cancer. 2001 Aug 1;92(3):519-23. doi: 10.1002/1097-0142(20010801)92:3<519::aid-cncr1350>3.0.co;2-#. Cancer. 2001. PMID: 11505395 Clinical Trial.

3

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

Vaishampayan U, Fontana J, Du W, Hussain M. Vaishampayan U, et al. Urology. 2002 Dec;60(6):1050-4. doi: 10.1016/s0090-4295(02)01990-8. Urology. 2002. PMID: 12475668 Clinical Trial.

4

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.

Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Hussain M, et al. Urology. 2003 Apr;61(4):774-80. doi: 10.1016/s0090-4295(02)02519-0. Urology. 2003. PMID: 12670564 Clinical Trial.

5

A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.

Hussain M, Vaishampayan U, Heilbrun LK, Jain V, LoRusso PM, Ivy P, Flaherty L. Hussain M, et al. Invest New Drugs. 2003 Nov;21(4):465-71. doi: 10.1023/a:1026259503954. Invest New Drugs. 2003. PMID: 14586215 Clinical Trial.

6

Racial disparity in incidence patterns and outcome of kidney cancer.

Vaishampayan UN, Do H, Hussain M, Schwartz K. Vaishampayan UN, et al. Urology. 2003 Dec;62(6):1012-7. doi: 10.1016/j.urology.2003.07.010. Urology. 2003. PMID: 14665346

7

Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.

Thatai LC, Banerjee M, Lai Z, Vaishampayan U. Thatai LC, et al. Urology. 2004 Oct;64(4):738-43. doi: 10.1016/j.urology.2004.05.024. Urology. 2004. PMID: 15491712 Review.

8

Phase II trial of fenretinide in advanced renal carcinoma.

Vaishampayan U, Heilbrun LK, Parchment RE, Jain V, Zwiebel J, Boinpally RR, LoRusso P, Hussain M. Vaishampayan U, et al. Invest New Drugs. 2005 Mar;23(2):179-85. doi: 10.1007/s10637-005-5864-7. Invest New Drugs. 2005. PMID: 15744595 Free article. Clinical Trial.

9

Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma.

Tripathi RT, Heilbrun LK, Jain V, Vaishampayan UN. Tripathi RT, et al. Among authors: vaishampayan un. Urology. 2006 Aug;68(2):296-301. doi: 10.1016/j.urology.2006.02.036. Urology. 2006. PMID: 16904440

10

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.

Vaishampayan UN, Heilbrun LK, Shields AF, Lawhorn-Crews J, Baranowski K, Smith D, Flaherty LE. Vaishampayan UN, et al. Invest New Drugs. 2007 Feb;25(1):69-75. doi: 10.1007/s10637-006-9005-8. Epub 2006 Aug 26. Invest New Drugs. 2007. PMID: 16937078 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters